| Jostein Dahle | |
| Position: | Scientist |
| Phone: | +47 22 78 12 03 |
| Email: | |
Office: +47 22 78 12 03
Fax: +47 22 78 12 07
Room: J4002 in the new Radiation Therapy building.
Mini CV
Jostein Dahle was born and spent his youth on Karmøy, an island on the south-western part of Norway. He is married, have three children and lives in Bærum, a suburb to Oslo.
He was awarded a master of science degree in Biophysics by the Norwgian Universty of Science and Technology in Trondheim in 1995, and a PhD by the University of Oslo in 2000. His doctoral work was performed at the Norwegian Radium Hospital, supervised by Johan Moan and Harald B. Steen and concerned the bystander effect in photodynamic treatment of cells. This was followed by a postdoctoral work at Egil Kvams lab at the Norwegian Radium Hospital. Here he worked on mechanisms for UV-radiation induced genomic instability. The PhD and Postdoc periods were fully financed by the Norwegian Research Council (NRC). In 2005 he got a scientist position at the Norwegian Radium Hospital financed by the MEDKAP program in the NRC. This was followed by a scientist position sponsored by the Norwegian Cancer Society from 2007 to 2009 and a new scientist positon sponsored by the Health Authorities of South Eastern Norway from 2010-2012. In 2009 he co-founded Nordic Nanovector AS in order to develop the research on radioimmunotherapy in to the clinic.
Commercial for the Norwegain Cancer Society with Jostein Dahle.
Research
Development of Radioimmunotherapy of cancer with alpha-emitting radioimmunconjugates based on the 227Th-DOTA ligand. The research is performed in collaboration with Algeta ASA.
Radioimmunotherapy of lymphoma with beta-emitting Lutetium-177 coupled to an antibody against lymphoma cells.
Previously, research concerned two photobiolgy projects: The bystander effect in photodynamic treatment of cells was studied during the PhD period. Molecular mechanisms for radiation-induced mutagenesis and genomic instability was studied during the postdoc period.
An automatic colony counter has been made to facilitate studies of mutagenesis, genomic instability and cell death.
Key publications
- Dahle, J., Kaalhus, O., Moan, J., Steen, H., B., Cooperative effects on cells treated with Photofrin and light. (1997) Proc. Natl. Acad. Sci. USA. 94 p. 1773-1778.
- Dahle, J., Kvam, E. Induction of delayed mutations and chromosomal instability in fibroblasts after UVA-, UVB- and X-radiation. (2003) Cancer Research 63 pp. 1464-1469.
- Dahle, J., Bruland, O.,Melhus, K. B., Borrebæk, J., Press, O., and Larsen, R. H. Targeted cancer therapy with a novel low-dose rate alpha-emitteing radioimmunoconjugate. (2007) Blood. 110(6), 2049-2056.
Education
PhD, radiation biology,University of Oslo, April 2000.
Master of Science, biophysics, Norwegian University for Science and Technology in Trondheim, December 1995.
Employment
Scientist at Department of Radiation Biology, The Norwegian Radium Hospital since December 2004.
Author network for Jostein Dahle by COREMINE medical
Publications 2012
Genome-wide microarray analysis of human fibroblasts in response to ? radiation and the radiation-induced bystander effect
Radiat Res, 177 (1), 35-43
PubMed 22034846
Publications 2011
Experimental ?-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab
EJNMMI Res, 1 (1), 18
PubMed 22214432
Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates
Curr Radiopharm, 4 (4), 321-8
PubMed 22202154
Dosimetry of a 238Pu-based alpha-particle irradiator and its biological application in a study of the bystander effect
Anticancer Res, 31 (6), 2113-20
PubMed 21737630
Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab
Int J Radiat Oncol Biol Phys, 79 (2), 563-70
PubMed 21195878
Publications 2010
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab
Eur J Nucl Med Mol Imaging, 37 (1), 93-102
PubMed 19593562
Publications 2009
In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab
Int J Radiat Oncol Biol Phys, 75 (3), 886-95
PubMed 19679402
A (238)Pu irradiator for exposure of cultured cells with alpha-radiation: construction, calibration and dosimetry
Appl Radiat Isot, 67 (11), 1998-2002
PubMed 19716308
Publications 2008
Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation
Int J Radiat Oncol Biol Phys, 72 (1), 186-92
PubMed 18722269
Overexpression of human OGG1 in mammalian cells decreases ultraviolet A induced mutagenesis
Cancer Lett, 267 (1), 18-25
PubMed 18406515
Publications 2007
Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate
Blood, 110 (6), 2049-56
PubMed 17536011
A one-step method for determining the maximum number of bound antibodies, and the affinity and association rate constants for antibody binding
Nucl Med Commun, 28 (9), 742-7
PubMed 17667754
Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability
Cancer Biother Radiopharm, 22 (3), 431-7
PubMed 17651051
Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th
Cancer Biother Radiopharm, 22 (4), 469-79
PubMed 17803441
Publications 2006
Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy
Nucl Med Biol, 33 (2), 271-9
PubMed 16546683
Publications 2005
Bystander effects in UV-induced genomic instability: antioxidants inhibit delayed mutagenesis induced by ultraviolet A and B radiation
J Carcinog, 4, 11
PubMed 16091149
Bystander effects may modulate ultraviolet A and B radiation-induced delayed mutagenesis
Radiat Res, 163 (3), 289-95
PubMed 15733036
Multiplex polymerase chain reaction analysis of UV-A- and UV-B-induced delayed and early mutations in V79 Chinese hamster cells
Photochem Photobiol, 81 (1), 114-9
PubMed 15453821
The pheomelanin precursor 5-S-cysteinyldopa protects melanocytes from membrane damage induced by ultraviolet A radiation
Cancer Lett, 221 (2), 131-4
PubMed 15808398
Publications 2004
Automated counting of mammalian cell colonies by means of a flat bed scanner and image processing
Cytometry A, 60 (2), 182-8
PubMed 15290719
Increased level of oxidative stress in genomically unstable cell clones
J Photochem Photobiol B, 74 (1), 23-8
PubMed 15043843
Melanin synthesis may sensitize melanocytes to oxidative DNA damage by ultraviolet A radiation and protect melanocytes from direct DNA damage by ultraviolet B radiation
Pigment Cell Res, 17 (5), 549-50
PubMed 15357843
Publications 2003
Induction of delayed mutations and chromosomal instability in fibroblasts after UVA-, UVB-, and X-radiation
Cancer Res, 63 (7), 1464-9
PubMed 12670891
Pigmented melanocytes are protected against ultraviolet-A-induced membrane damage
J Invest Dermatol, 121 (3), 564-9
PubMed 12925216
Publications 2001
Bystander effects in cell death induced by photodynamic treatment UVA radiation and inhibitors of ATP synthesis
Photochem Photobiol, 73 (4), 378-87
PubMed 11332033
Publications 2000
The bystander effect in photodynamic inactivation of cells
Biochim Biophys Acta, 1475 (3), 273-80
PubMed 10913826
Gap junctional intercellular communication is not a major mediator in the bystander effect in photodynamic treatment of MDCK II cells
Radiat Res, 154 (3), 331-41
PubMed 10956441
Publications 1999
Cooperative inactivation of cells in microcolonies treated with UVA radiation
Radiat Res, 152 (2), 174-9
PubMed 10409327
Cooperative effects of photosensitized cell killing
P SOC PHOTO-OPT INS, 3563, 120-124
The mode of cell death induced by photodynamic treatment depends on cell density
Photochem Photobiol, 70 (3), 363-7
PubMed 10483366
Publications 1997
Cooperative effects of photodynamic treatment of cells in microcolonies
Proc Natl Acad Sci U S A, 94 (5), 1773-8
PubMed 9050854
Go back
Print this page
E-mail this page
